Alessandra Piccirilli

Dr. Alessandra Piccirilli

Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
Luigi PrincipeLuigi Principe
Luigi Principe
Stefano Di BellaStefano Di Bella
Stefano Di Bella
JCJacopo Conti
Jacopo Conti
Mariagrazia PerilliMariagrazia Perilli
Mariagrazia Perilli
Alessandra PiccirilliAlessandra Piccirilli
Alessandra Piccirilli
GDGiuliana Decorti
Giuliana Decorti
Infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) have limited therapeutic options. Sulbactam-durlobactam is a combination of two βlactamase inhibitors with activity against CRAB under phase 3 clinical investigation. We performed a systematic review on in vitro studies reporting A. baumannii resistances against sulbactam/durlobactam. We considered “resistant” species to be those with MIC ≥ 8 mg/L. Ten studies were included in the review (9754 tested isolates). Overall, 2.3% of A. baumannii were resistant to sulbactam/durlobactam, and this percentage rose to 3.4% among CRAB subgroups and to 3.7% among colistin-resistant strains. Resistance was 100% among metallo β-lactamase-producing strains. Overall, in 12.5% of cases, sulbactam/durlobactam resistance was associated with the production of NDM-1, in 31.7% of cases with the substitutions in the PBP3 determinants, and in the remaining cases the resistance mechanism was unknown. In conclusion, A. baumannii resistance towards sulbactam/durlobactam is limited, except for MBL-producing strains.

27 December 2020 in Microorganisms
Verified
Journal Article
Open access
PDF file
Arianna PompilioArianna Pompilio
Arianna Pompilio
MRMarco Ranalli
Marco Ranalli
Alessandra PiccirilliAlessandra Piccirilli
Alessandra Piccirilli
Mariagrazia PerilliMariagrazia Perilli
Mariagrazia Perilli
DVDragana Miroslav Vukovic
Dragana Miroslav Vukovic
Giovanni Di BonaventuraGiovanni Di Bonaventura
Giovanni Di Bonaventura
The ability to form biofilms is a recognized trait of Stenotrophomonas maltophilia, but the extent of its clinical relevance is still unclear. The present multicenter prospective study (ANSELM) aims at investigating the association between biofilm formation and clinical outcomes of S. maltophilia infections. One hundred and nine isolates were collected from various geographical origins and stratified according to their clinical relevance. Biofilm formation was evaluated by the microtiter plate assay and correlated with microbiological and clinical data from the associated strains. Antibiotic susceptibility of the planktonic cells was tested by the disk diffusion technique, while antibiotic activity against mature biofilms was spectrophotometrically assessed. Most strains (91.7%) were able to form biofilm, although bloodborne strains produced biofilm amounts significantly higher than strains causing hospital- rather than community-acquired infections, and those recognized as “definite” pathogens. Biofilm formation efficiency was positively correlated with mechanical ventilation (p = 0.032), whereas a negative relationship was found with antibiotic resistance (r2 = 0.107; p < 0.001), specifically in the case of the pathogenic strains. Mature S. maltophilia biofilms were markedly more resistant (up to 128 times) to cotrimoxazole and levofloxacin compared with their planktonic counterparts, especially in the case of bloodborne strains. Our findings indicate that biofilm formation by S. maltophilia is obviously a contributing factor in the pathogenesis of infections, especially in deep ones, thus warranting additional studies with larger cohort of patients and isolates.

17 August 2023 in Microbiology Spectrum
Verified
Journal Article
Open access
Giovanni Di BonaventuraGiovanni Di Bonaventura
Giovanni Di Bonaventura
VLVeronica Lupetti
Veronica Lupetti
AGAndrea Di Giulio
Andrea Di Giulio
MMMaurizio Muzzi
Maurizio Muzzi
Alessandra PiccirilliAlessandra Piccirilli
Alessandra Piccirilli
Arianna PompilioArianna Pompilio
Arianna Pompilio
Antibiotic resistance makes it urgent to design new strategies for treating pulmonary infections in CF patients. The repurposing approach accelerates drug discovery and development, as the drugs’ general pharmacological, pharmacokinetic, and toxicological properties are already well known.

15 July 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
SCSabrina Cherubini
Sabrina Cherubini
Mariagrazia PerilliMariagrazia Perilli
Mariagrazia Perilli
BSBernardetta Segatore
Bernardetta Segatore
PFPaolo Fazii
Paolo Fazii
GPGiustino Parruti
Giustino Parruti
Alessandra PiccirilliAlessandra Piccirilli
Alessandra Piccirilli
A total of 43 A. baumannii strains, isolated from 43 patients affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and by bacterial sepsis, were analyzed by antimicrobial susceptibility testing. All strains were resistant to almost three different classes of antibiotics, including carbapenems and colistin. The whole-genome sequencing (WGS) of eight selected A. baumannii isolates showed the presence of different insertion sequences (ISs), such as ISAba13, ISAba26, IS26, ISVsa3, ISEc29, IS6100 and IS17, giving to A. baumannii a high ability to capture and mobilize antibiotic resistance genes. Resistance to carbapenems is mainly mediated by the presence of OXA-23, OXA-66 and OXA-82 oxacillinases belonging to OXA-51-like enzymes. The presence of AmpC cephalosporinase, ADC-25, was identified in all A. baumannii. The pathogenicity of A. baumannii was exacerbated by the presence of several virulence factors. The multi-locus sequence typing (MLST) analysis showed that all strains belong to sequence type 2 (ST) international clone.

17 September 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
Alessandra PiccirilliAlessandra Piccirilli
Alessandra Piccirilli
SCSabrina Cherubini
Sabrina Cherubini
AAAnna Maria Azzini
Anna Maria Azzini
ETEvelina Tacconelli
Evelina Tacconelli
Giuliana Lo CascioGiuliana Lo Cascio
Giuliana Lo Cascio
Mariagrazia PerilliMariagrazia Perilli
Mariagrazia Perilli
K. pneumoniae (KPN) is one of the widest spread bacteria in which combined resistance to several antimicrobial groups is frequent. The most common β-lactamases found in K. pneumoniae are class A carbapenemases, both chromosomal-encoded (i.e., NMCA, IMI-1) and plasmid-encoded (i.e., GES-enzymes, IMI-2), VIM, IMP, NDM, OXA-48, and extended-spectrum β-lactamases (ESBLs) such as CTX-M enzymes. In the present study, a total of 68 carbapenem-resistant KPN were collected from twelve long-term care facilities (LTCFs) in the Northern Italian region. The whole-genome sequencing (WGS) of each KPN strain was determined using a MiSeq Illumina sequencing platform and analysed by a bacterial analysis pipeline (BAP) tool. The WGS analysis showed the prevalence of ST307, ST512, and ST37 as major lineages diffused among the twelve LTCFs. The other lineages found were: ST11, ST16, ST35, ST253, ST273, ST321, ST416, ST1519, ST2623, and ST3227. The blaKPC-2, blaKPC-3, blaKPC-9, blaSHV-11, blaSHV-28, blaCTX-M-15, blaOXA-1, blaOXA-9, blaOXA-23, qnrS1, qnrB19, qnrB66, aac(6′)-Ib-cr, and fosA were the resistance genes widespread in most LTCFs. In this study, we demonstrated the spreading of thirteen KPN lineages among the LTCFs. Additionally, KPC carbapenemases are the most widespread β-lactamase.

22 August 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
BSBernardetta Segatore
Bernardetta Segatore
Alessandra PiccirilliAlessandra Piccirilli
Alessandra Piccirilli
SCSabrina Cherubini
Sabrina Cherubini
Luigi PrincipeLuigi Principe
Luigi Principe
GAGiovanni Alloggia
Giovanni Alloggia
Mariagrazia PerilliMariagrazia Perilli
Mariagrazia Perilli
In the present study, the in vitro activity of the sulbactam–durlobactam (SUL–DUR) combination was evaluated against 141 carbapenem-resistant A. baumannii (CRAb) clinical strains collected from six Italian laboratories. Over half (54.6%) of these isolates were resistant to colistin. The SUL–DUR combination was active against these CRAb isolates with MIC50 and MIC90 values of 0.5 mg/L and 4 mg/L, respectively. Only eleven isolates were resistant to SUL–DUR with MIC values ranging from 8 to 128 mg/L. The SUL–DUR resistant A. baumannii exhibited several antimicrobial resistance genes (ARGs) such as blaOXA-20, blaOXA-58, blaOXA-66, blaADC-25, aac(6′)-Ib3 and aac(6′)-Ib-cr and mutations in gyrA (S81L) and parC (V104I, D105E). However, in these isolates, mutations Q488K and Y528H were found in PBP3. Different determinants were also identified in these CRAb isolates, including adeABC, adeFGH, adeIJK, abeS, abaQ and abaR, which encode multidrug efflux pumps associated with resistance to multiple antibacterial agents. This is the first report on the antimicrobial activity of SUL–DUR against carbapenem-resistant A. baumannii isolates selected from multiple regions in Italy.